165 results
8-K
EX-99.1
SNGX
Soligenix Inc
22 Apr 24
Soligenix Announces Pricing of $4.75 Million Public Offering
4:05pm
in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives
424B4
SNGX
Soligenix Inc
19 Apr 24
Prospectus supplement with pricing info
4:05pm
success in commercializing some of our product candidates.
Our products, if approved, may not be commercially viable due to change in health care practice … to treat the same conditions and our revenue will be reduced.
Federal and/or state health care reform initiatives could negatively affect our business.
We
8-K
EX-99.1
SNGX
Soligenix Inc
3 Apr 24
Randomized Study with 18 Weeks Continuous Treatment Expected to Replicate and Extend Results from the First, Statistically Significant Phase 3 Study
4:05pm
, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third … party reimbursement limitations and Federal and/or state health care reform initiatives will not negatively affect its business, or that the U.S
8-K
EX-99.1
uxp39
17 Nov 23
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
4:05pm
8-K
EX-99.1
oqt9qv 3odm
20 Oct 23
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
4:05pm
8-K
EX-99.1
7ujyzmd37eosf5tl2
22 Sep 23
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
EX-99.1
8itnji0ic
9 May 23
Soligenix Announces Pricing of $8.5 Million Public Offering
4:15pm
8-K
EX-99.2
c71pk
9 May 23
Soligenix Announces Pricing of $8.5 Million Public Offering
4:15pm
8-K
EX-99.1
m25wkkq3eon2nefilw5l
1 May 23
Soligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet’s Disease
7:45am
8-K
EX-99.1
psnnn fino
27 Dec 22
Soligenix Announces Distribution of Series D Preferred Stock to Holders of its Common Stock
4:25pm
8-K
EX-99.1
rfi0v
19 Dec 22
Other Events
8:00am
8-K
EX-99.1
0i9bwrz eild
15 Dec 22
Soligenix Announces Submission of New Drug Application to the FDA for HyBryte™ in the Treatment of Cutaneous T-cell Lymphoma
8:14am